Carney Picks Canadian Pension Executive as Next Chief of Staff
The Caisse de dépôt et placement du Québec said in a release Sunday that Marc-André Blanchard, executive vice-president and head of CDPQ Global and and global head of sustainability, was leaving to become Carney's chief of staff.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Canada Stands with Ukraine. Now Ukrainians Stand with Canada.
Canada-Ukraine Foundation and Ukrainian Canadian Congress donate $100,000 to the Canadian Red Cross in support of the Manitoba and Saskatchewan Wildfires Appeals Photo Credit: Alexis Aubin/Canadian Red Cross TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- In a heartfelt gesture of solidarity and gratitude, the and the Ukrainian Canadian Congress (UCC) announced a $100,000 donation to the Canadian Red Cross to help meet the needs of people impacted by wildfires in Manitoba and Saskatchewan. Since Russia's full-scale invasion in February 2022, Canadians have stood with Ukraine in extraordinary ways. Together, CUF and UCC, through the Ukraine Humanitarian Appeal (UHA), have raised and committed over $95 million in aid, impacting the lives of more than 6 million Ukrainians. Much of that support has come from communities now facing their own crisis. "As wildfires destroy homes, displace families, and blanket communities in smoke, we see firsthand the toll this emergency is taking on Canadians, many of whom stood with Ukrainians when they needed them most," . "This donation is our way of standing with Canadians now." 'We are grateful to the Canada-Ukraine Foundation and the Ukrainian Canadian Congress for their generous support that will benefit people impacted by wildfires in Manitoba and Saskatchewan,' . 'As we continue to respond to one of the worst wildfire seasons in the prairies, the Red Cross is committed to helping people while they are away from home and as they begin to recover.' 'Our hearts go out to our neighbours whose lives and homes are affected by these wildfires,' said Alexandra Chyczij, National President, Ukrainian Canadian Congress. 'The Ukrainian Canadian Congress will do all we can to support these communities during their time of need.' The $100,000 contribution to the Canadian Red Cross will be used for assisting those impacted by the wildfires in Manitoba and Saskatchewan with immediate and ongoing relief. This includes financial assistance, support to evacuees and the communities hosting them, recovery and resilience efforts in response to the wildfires, as well as supporting community preparedness and risk reduction for future all-hazard disaster events within Manitoba and Saskatchewan. United by care and driven by community, CUF and UCC reaffirm their ongoing commitment to the Canadian communities that continue to make their work possible. To donate and learn more about the CUF, please visit Social Media: Instagram: @canadaukrainefoundation Facebook: @cufoundation YouTube: @canada-ukrainefoundation2010 Media Contacts:Zai Karim zai@ - 647-983-6669Shannon Kenney shannon@ - 416-770-0359 About the Canada-Ukraine Foundation Founded in 1995 during the 18th Ukrainian Canadian Congress (UCC), the Canada-Ukraine Foundation (CUF) was established to coordinate, develop, and deliver humanitarian assistance from Canadians to Ukraine. CUF continues to play a vital role as a national charitable foundation, working to monitor, promote, and support humanitarian aid initiatives. Its mission includes evaluating projects, fostering collaboration among aid providers, setting strategic priorities, and ensuring resources are directed where they can have the greatest impact. CUF also serves as a forum for individuals and organizations—across community, private, and public sectors—committed to supporting Ukraine. In addition to its work abroad, CUF also supports related initiatives within Canada. To learn more: About the CUF-UCC Ukraine Humanitarian Appeal A joint initiative of the Canada-Ukraine Foundation (CUF) and the Ukrainian Canadian Congress (UCC), the CUF-UCC Ukraine Humanitarian Appeal (UHA) was launched in January 2022 to coordinate the efficient delivery of humanitarian aid in response to Russia's full-scale invasion of Ukraine. Its efforts focus on supporting displaced persons, medical care, emergency shelter, and food security—both in Ukraine and among those displaced to Europe and Canada. To date, the UHA has delivered over $95 million in aid, helping more than 6 million people. A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings
Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people will die from the disease, which is equivalent to about 1,700 deaths each day. The scale of this health crisis is driving substantial investments and innovation in cancer research and treatment. As a result, the global oncology market is projected to reach $208.9 billion in revenue by 2025, with forecasts suggesting it could surpass $900 billion by 2034. This growth is fueled by increased cancer incidence, advances in precision and immunotherapy drugs, and billions of dollars in new partnerships and funding, such as Bristol-Myers Squibb's (BMY) recent $11 billion stake in next-generation cancer therapies. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. High-potential cancer specialists like Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are earning coveted 'Strong Buy' analyst ratings. Despite this recognition, each remains well below large-cap valuations, which leaves ample room for sharp upside if upcoming clinical and regulatory catalysts play out in their favor. Could one of these under-the-radar biotech firms deliver the next big breakthrough in cancer treatment — and major upside for investors? Let's dive into these three cancer biotech stocks now. Elicio Therapeutics Elicio Therapeutics (ELTX) is a clinical-stage biotech pioneering immunotherapies for solid tumors, with a market capitalization of $158 million. ELTX has posted a YTD gain of 92.7%, and is up 102.6% over the past 52 weeks. Its price-book ratio stands at an elevated 17.6x, well above the sector median of 2.47x. Elicio's lead asset, ELI-002 7P, is advancing through the pivotal Phase 2 AMPLIFY-7P trial targeting pancreatic ductal adenocarcinoma (PDAC), with a critical interim analysis focused on disease-free survival slated for Q3 2025. This interim analysis is a key milestone for the company, particularly for its potential impact on PDAC. Ahead of this readout, H.C. Wainwright analyst Robert Burns reiterated a 'Buy' rating on shares and maintained his $13 price target. Elicio reported Q1 2025 R&D expenses of $7.8 million, a slight increase from $7.6 million in Q1 2024, tied primarily to the ongoing Phase 2 AMPLIFY-7P trial. General and administrative expenses grew to $3 million, up from $2.7 million due to higher personnel costs. The Q1 2025 net loss narrowed to $11.2 million, compared to $11.8 million in the same quarter last year, with a net loss per share improving to $0.87 from $1.15. Notably, ELTX augmented its financial position in Q2 by securing a $10 million senior secured note, extending its operational runway into early 2026 and granting the company flexibility for near-term initiatives. Analyst sentiment skews highly bullish as the two surveyed analysts assign ELTX a 'Strong Buy' rating, with an average price target of $12.50. This places the upside potential at approximately 26% from current levels. Cellectis Cellectis (CLLS) is a clinical-stage biotech company specializing in gene-edited cell therapies with a market capitalization of approximately $140 million. The stock has gained 60% in the year to date, and shares are up 25.2% in the past 52 weeks. Cellectis has a price-sales ratio of 2.26x, below the sector median of 3.6x, and a price-book ratio of 0.96x, significantly under the sector median of 2.47x, suggesting potential undervaluation relative to its peers. CLLS reported solid results for Q1 2025, with consolidated revenues and other income rising to $12 million from $6.5 million a year prior. This increase mainly stems from $5.9 million recognized under the AstraZeneca Joint Research Collaboration Agreement (AZ JRCA). Its cash reserves stood at $246 million as of March 31, 2025, projected to sustain operations well into the second half of 2027, providing ample runway for ongoing development. Research and development expenses slightly decreased to $21.9 million compared to the previous year, reflecting efficient management despite continued investment in pipeline advancement and manufacturing capabilities in Paris and Raleigh. Strategically, Cellectis' partnership with AstraZeneca is a cornerstone of its growth story. AstraZeneca's $140 million investment enhances Cellectis' financial footing and grants AstraZeneca exclusive rights to 25 genetic targets, with options to develop up to 10 candidate products. So far this collaboration is advancing two CAR-T programs aimed at hematological malignancies and solid tumors. Analyst sentiment is unanimously bullish, with the five surveyed analysts assigning Cellectis a consensus 'Strong Buy' rating. The average price target of $5.60 implies compelling upside of approximately 91% from the current share price. Autolus Therapeutics Autolus Therapeutics (AUTL) develops advanced autologous CAR-T cell therapies for blood cancers, with a market capitalization of $670 million. The stock is up 8.7% year-to-date, but down 45% over the past 52 weeks. Its price-sales ratio of 69.4xx is markedly above the sector's 3.54x median, while its 1.89x price-book ratio remains below group averages of 2.47x. In Q1 2025, Autolus reported $9 million in net product revenue, driven largely by the commercial rollout of AUCATZYL (Obe-cel), its lead CAR-T therapy, across 39 fully activated U.S. centers. Patient access continues to grow, capturing coverage for roughly 90% of U.S. medical lives as payer uptake accelerates. Costs of sales totaled $18 million, including delivered but as-yet-unrecognized product tied to deferred revenue and royalty obligations, a natural part of early stage commercial launches. Research and development expenses dropped to $26.7 million from $30.7 million year-over-year, with much of that shift driven by the transition of manufacturing expenses to sales costs. Loss from operations widened to $65.2 million due to launch investments, and net loss reached $70.2 million or $0.26 per share. On the regulatory front, Autolus scored a critical win in July as AUCATZYL secured European approval for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This unlocks a larger addressable market and enhances the company's global competitive position in engineered cell therapies. The analyst outlook remains unequivocally positive as the nine surveyed analysts rate AUTL a consensus 'Strong Buy,' with a mean target of $9.84, implying 285% upside potential from current levels. Conclusion With major catalysts ahead and strong analyst backing, the odds favor upward momentum as data readouts and commercial expansion play out. Given their positioning and partnerships, these three stocks could deliver outsized gains in the coming quarters, especially if results come in strong. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
5 minutes ago
- Yahoo
Organizations Risk Losing Top Talent Without Clear Career Pathing, Says HR Research Firm McLean & Company
As employees continue to seek meaningful development and internal mobility, many organizations are falling short in providing the clarity and support needed to retain top talent. McLean & Company's recent research, Develop an Integrated Career Pathing Framework, addresses this critical gap with a practical, evidence-based approach that empowers HR leaders to build transparent, scalable career development strategies aligned to both employee aspirations and organizational goals. TORONTO, July 28, 2025 /CNW/ - With only one in five employees confident in their ability to make an internal career move (LinkedIn, 2024), and 43% of exiting employees citing a lack of advancement opportunities as a reason for leaving (McLean & Company Exit Survey, 2021-2024), organizations face mounting pressure to address the widening gap between employee ambition and organizational opportunities. Yet despite this rising employee demand for internal mobility, most organizations are failing to effectively support their employees in navigating their career growth. McLean & Company's latest research insights, Develop an Integrated Career Pathing Framework, offers a practical, evidence-based approach to designing career pathing initiatives that not only deepen employee commitment but also build the foundation for sustainable organizational growth. By connecting individual development with broader business goals, the framework helps HR leaders and their organizations unlock internal talent potential and create more resilient, future-ready workforces. "Employees are telling us they want to grow – but they don't see a path forward," said Lexi Hambides, director, HR Research & Advisory Services at McLean & Company. "Our research shows that when career pathing frameworks are unclear or non-existent, employees disengage, seek opportunities elsewhere, and organizations struggle to retain critical talent. A well-designed, transparent framework aligns employee aspirations with business needs, enabling internal mobility, improving role fit, and ultimately driving stronger organizational performance." McLean & Company's research highlights that while career development is a proven driver of employee engagement, many organizations struggle to implement frameworks that are scalable, relevant, and responsive to the evolving needs of their workforce. The HR research and advisory firm explains that career pathing initiatives frequently stall due to limited resources, insufficient leadership alignment, and a lack of integration with broader HR programs such as learning and development, internal mobility, and total rewards. McLean & Company's data shows that employees who believe their organization provides adequate opportunities to learn new skills are 1.6 times more likely to be engaged (McLean & Company Exit Survey, 2021–2024), an insight that reinforces the recommendation for well-structured, transparent, and future-ready career development strategies. Introducing McLean & Company's Career Pathing Framework To close the disconnect between employee expectations and organizational support, the new framework offers a structured yet adaptable approach to career pathing. McLean & Company's resource guides HR teams through key activities such as: Defining role levels and progression criteria. Mapping clear mobility pathways across functions and levels. Aligning career growth with performance expectations and organizational priorities. By enabling employees to envision and pursue growth within their organization, career pathing fosters a sense of purpose, connection, and loyalty, factors that are becoming increasingly critical in today's talent market. At the core of the framework is McLean & Company's thought model, which outlines four key drivers of effective career pathing: Role clarity and leveling. Defined mobility criteria. Connection to HR systems (e.g. L&D, performance, total rewards). Manager enablement through tools and language to support continuous career growth. The firm's collective of research insights offers step-by-step guidance, tools, and templates to help HR leaders design and implement effective career pathing strategies tailored to their organization's needs. To learn more, please visit McLean & Company's Develop an Integrated Career Pathing Framework. McLean & Company's On-Demand Career Pathing Course As part of its comprehensive support, McLean & Company also offers an on-demand McLean Academy course called Career Pathing, which helps HR professionals apply the framework in real-world settings, strengthen internal capabilities, and lead effective change. Members can gain access to a robust set of tools and templates, including the Career Path Planning Workbook, the Create an Inclusive Promotion Process Guide, and a Goal Management Guide to support manager-employee development conversations. Media Inquiries for HR Analysts at McLean & Company For media inquiries or to connect with McLean & Company analysts for exclusive, research-backed insights on human resources, career pathing, engagement, and employee experience, please contact Communications Manager Katie Tame at ktame@ About McLean & Company McLean & Company pairs evidence-based research and immediately applicable tools with deep HR expertise to position organizations to meet today's needs and prepare for the future. The global HR research and advisory firm's member organizations enjoy comprehensive resources, full – service diagnostics, workshops, action plans, and advisory services for all levels of HR professionals, from executive leadership to HR leaders to HR team members, that help shape workplaces where everyone thrives. McLean & Company is a division of Info-Tech Research Group. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact ktame@ View original content to download multimedia: SOURCE McLean & Company View original content to download multimedia: Sign in to access your portfolio
